Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00566904
Other study ID # R43AR052998
Secondary ID 1R43AR052998-01H
Status Completed
Phase Phase 1
First received September 10, 2007
Last updated August 29, 2011
Start date September 2006
Est. completion date September 2008

Study information

Verified date August 2011
Source Biomedical Development Corporation
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Shingles is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chicken pox. Some people experience continued pain even after the shingles rash and blisters have healed; this pain is known as postherpetic neuralgia. The purpose of this study is to evaluate the effectiveness of a new topical treatment for postherpetic neuralgia in adults.


Description:

After an initial infection of chicken pox, the varicella-zoster virus can remain dormant inside nerve cells. Years later, the virus can be reactivated, causing a repeat outbreak called shingles. The first symptom of shingles is usually a burning or tingling pain in one particular location and on one side of the body. This pain can range from mild to severe. Other possible symptoms of shingles include numbness and itching. After several days or 1 week, a rash of fluid-filled blisters similar to chicken pox appears. For most healthy people, a case of shingles heals within a month. However, some people continue to feel pain after the rash and blisters have resolved; this pain is known as postherpetic neuralgia. Current treatments for postherpetic neuralgia include antiviral drugs, steroids, antidepressants, anticonvulsants, and topical products. A new topical treatment consists of a liquid product that is applied directly to the skin to let dry and form a thin, transparent barrier film. In contrast to creams or ointments that can stay in contact with skin for only minutes, this product remains intact on the skin for many hours, providing sustained delivery of a drug or medication while maintaining barrier protection for the skin. The purpose of this study is to evaluate the effectiveness of this new topical treatment for postherpetic neuralgia in adults.

This study will last about 3 weeks and will include seven study visits on Days 1, 8, 9, 15, 16, 22, and 23. All study visits will include questionnaires on pain levels and an examination and digital photos of the affected skin area. The study visit on Day 1 will also include a urine pregnancy test and a review of medical and medication history. During the study visits on Days 8, 15, and 22, one of three topical products will be applied to participants' affected skin. The product will dry on the skin in 30 to 45 seconds. Participants will then wait at the study site for 1.5 hours, after which they will record the time when they experienced pain relief. At each of these three treatment visits, participants will receive one of the following three topical products: Epikeia coatings with aspirin, Epikeia coatings with local anesthetic, and Epikeia coatings alone. At these three study visits, questionnaires, examinations, and digital photographs will occur both before and after the products are applied to the skin. Throughout the study, participants will record their pain levels and medications in a diary, which will be reviewed at all study visits.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date September 2008
Est. primary completion date August 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- In good general health

- Postherpetic neuralgia, defined as pain persisting more than 4 months after onset of herpes zoster outbreak

- Willing to use effective forms of contraception for the duration of the study

Exclusion Criteria:

- Known lidocaine sensitivity or allergy

- Inability to discontinue use of any nonstudy lidocaine-containing products for the duration of the study

- Known hypersensitivity to aspirin

- Open herpes zoster blisters

- Known sensitivity or allergy to an amide-type local anesthetic agent

- Existing conditions that make participation unsafe

- Pregnant

- Immunocompromised (e.g., HIV infected)

- Herpes zoster in any dermatome (area of skin innervated by a specific sensory nerve) affecting the face or scalp

- Affected skin area is greater than 420 square cm

- Affected area includes skin breakdown or nonintact skin

- Affected area consists of more than one contiguous area

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Epikeia coatings with aspirin
Applied to affected skin area using a roll-on ball applicator
Epikeia coatings with lidocaine
Applied to affected skin area using a roll-on ball applicator
Other:
Epikeia coatings alone
Applied to affected skin area using a roll-on ball applicator

Locations

Country Name City State
United States Dermatology Clincial Reseach Center Houston Texas

Sponsors (3)

Lead Sponsor Collaborator
Biomedical Development Corporation National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Latency to analgesia onset and duration of analgesia measures Between 8 and 16 hours after treatment application No
Secondary Skin irritation potential Between 8 and 24 hours after treatment application Yes
See also
  Status Clinical Trial Phase
Completed NCT04546334 - Erector Spinae Plane Block in Post-herpetic Neuralgia N/A
Terminated NCT01744522 - Leech Therapy for Postherpetic Neuralgia N/A
Completed NCT01688947 - Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00478179 - Study of a Bupivacaine Patch (Eladurâ„¢) to Treat Post- Herpetic Neuralgia Phase 2
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Terminated NCT01603394 - Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia Phase 4
Completed NCT01251211 - Botulinum Toxin in Peripheral Neuropathic Pain Phase 4
Completed NCT01228838 - Study of NGX-1998 for the Treatment of Postherpetic Neuralgia Phase 2
Completed NCT00612105 - Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN) Phase 2
Recruiting NCT04560361 - The Analgesic Effect of Electroacupuncture on Postherpetic Neuralgia N/A
Recruiting NCT05568186 - Correlation Between Thermal Patterns of Infrared Thermal Imaging and Clinical Phenotype in Patients With Postherpetic Neuralgia
Recruiting NCT04664530 - The Study on the Esketamine in the Treatment of Postherpetic Neuralgia Phase 4
Active, not recruiting NCT01508676 - Effects of Pennsaid on Clinical Neuropathic Pain N/A
Completed NCT00885586 - Acupuncture in Herpes Zoster Neuralgia (ACUZoster) Phase 4
Completed NCT00981227 - Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia Phase 2
Completed NCT00576108 - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00238511 - An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00007501 - Shingles Prevention Study Phase 3
Completed NCT04594226 - Electroacupuncture Therapy for Treating Postherpetic Neuralgia N/A
Completed NCT05140863 - To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia Phase 3